Furthermore, when the Korean Diabetes Association [3] published its revised diabetes guidelines, it added an indicator of CGM devices to the glycemic control target and recommended the use of real-time CGM for people with type 2 diabetes treated with multiple insulin injections, as well as emphasizing the need for thorough diabetes management and training, including insulin dosing and proper device usage education for patients. The gene discussed is INS; the disease is type 2 diabetes mellitus.